Biolinq raises $58M to support intradermal glucose sensor

Written by

Sean Whooley

Biolinq announced today that it completed a $58 million financing to support the progression of its proprietary intradermal glucose sensor.

Alpha Wave Ventures led the funding round. Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures also participated. Other contributors included existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital and Taisho Pharmaceutical.

San Diego-based Biolinq plans to use the funds to support the completion of a U.S. pivotal clinical trial of its glucose sensor this year. Funds may also go toward a subsequent FDA submission.

Full article here: https://www.massdevice.com/biolinq-raises-58m-intradermal-glucose-sensor/

‍

Other news

BioWorld

June 2, 2024

Biolinq: Less pain, $58m gain for tiny glucose sensor

In a sweet indication of an improving capital market for med-tech companies, Biolinq Inc. landed $58 million in bridge financing to support completion of the U.S. pivotal trial of its intradermal glucose sensor and submission to the U.S. FDA.

Written by

Anette Boyle

Medical Device Network

June 2, 2024

Biolinq raises $58m for glucose microsensor pivotal trial

Biolinq is eying an FDA application this year, according to CEO Richard Yang. “The pivotal study started in March 2024 and we plan to file for US Food and Drug Administration (FDA) clearance this year.” said Yang.

Biolinq lands $58m to advance wearable metabolic health technology

Health tech company Biolinq has secured $58 million in new funding to advance its biosensor technology for enhancing metabolic health. Company targets clinical trial of groundbreaking CGM device that detects blood glucose levels just below the surface of the skin.

Written by

Danny Sullivan